<SEC-DOCUMENT>0001104659-25-014546.txt : 20250218
<SEC-HEADER>0001104659-25-014546.hdr.sgml : 20250218
<ACCEPTANCE-DATETIME>20250218081605
ACCESSION NUMBER:		0001104659-25-014546
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250218
DATE AS OF CHANGE:		20250218

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nukkleus Inc.
		CENTRAL INDEX KEY:			0001787518
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				383912845
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92171
		FILM NUMBER:		25632811

	BUSINESS ADDRESS:	
		STREET 1:		525 WASHINGTON BLVD
		CITY:			JERSEY CITY
		STATE:			NJ
		ZIP:			07310
		BUSINESS PHONE:		212-791-4663

	MAIL ADDRESS:	
		STREET 1:		525 WASHINGTON BLVD
		CITY:			JERSEY CITY
		STATE:			NJ
		ZIP:			07310

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brilliant Acquisition Corp
		DATE OF NAME CHANGE:	20190909

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Esousa Group Holdings LLC
		CENTRAL INDEX KEY:			0002033034
		ORGANIZATION NAME:           	
		IRS NUMBER:				881214533
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		211 EAST 43RD STREET, SUITE 402
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		646-278-6785

	MAIL ADDRESS:	
		STREET 1:		211 EAST 43RD STREET, SUITE 402
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-24-131196</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Esousa Group Holdings LLC -->
          <cik>0002033034</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001787518</issuerCik>
        <issuerName>Nukkleus Inc.</issuerName>
        <issuerCusip>67054R104</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>525 Washington Blvd.</com:street1>
          <com:city>Jersey City</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07310</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Esousa Group Holdings LLC</reportingPersonName>
      <citizenshipOrOrganization>NY</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3958332.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3958332.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3958332.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Michael Wachs</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3958332.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3958332.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3958332.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Nukkleus Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>525 Washington Blvd. Jersey City, NJ, 07310</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Esousa Group Holdings LLC and Michael Wachs.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>211 East 43rd Street, Suite 402
New York, NY 10017</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Esousa Group Holdings LLC is a New York limited liability company and Mr. Wachs is a U.S. citizen.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>3,958,332. This amount consists of (i) 230,000 shares of common stock, (ii) 1,353,333 shares of common stock issuable upon exercise of pre-funded warrants ("Pre-Funded Warrants") sold by the Issuer to the Reporting Person on December 18, 2024 and (iii) 2,374,999 shares of common stock issuable upon exercise of warrants ("Warrants") sold by the Issuer to the Reporting Person on December 18, 2024. This amount reflects the number of shares of common stock that would be issuable upon full exercise of such reported securities and does not give effect to applicable beneficial ownership limitations. Therefore, the actual number of shares of common stock beneficially owned by the Reporting Person, after giving effect to such beneficial ownership limitations, is less than the number of securities reported in this Item 4(a).</amountBeneficiallyOwned>
        <classPercent>9.99%. This percentage assumes the issuance of shares of common stock upon exercise of the Pre-Funded Warrants and Warrants, which are subject to, respectively, the PFW Beneficial Ownership Limitation and the Warrant Beneficial Ownership Limitation (each as defined below), and is based on 4,660,431 shares of common stock, which includes (i) 3,222,931 shares of common stock outstanding as of December 18, 2024, (ii) 230,000 shares of common stock issued to the Reporting Person and (iii) 1,437,500 shares of common stock issued to executive officers, directors and consultants.

Pursuant to the terms of the Pre-Funded Warrants, the Issuer cannot issue shares of common stock to the Reporting Person, and the Reporting Person cannot exercise the Pre-Funded Warrants, to the extent that the Reporting Person would beneficially own, after any such issuance or exercise, more than 4.99% of the then issued and outstanding shares of common stock (the "PFW Beneficial Ownership Limitation"), and the percentage set forth in this Item 4(b) gives effect to the PFW Beneficial Ownership Limitation. Consequently, due to the PFW Beneficial Ownership Limitation, as of the date of the event which requires filing of this statement, the Reporting Person could not exercise all of the Pre-Funded Warrants. The holder of the Pre-Funded Warrants, upon notice to the Issuer, may increase the PFW Beneficial Ownership Limitation to up to 9.99%

Pursuant to the terms of the Warrants, the Issuer cannot issue shares of common stock to the Reporting Person, and the Reporting Person cannot exercise the Warrants, to the extent that the Reporting Person would beneficially own, after any such issuance or exercise, more than 9.99% of the then issued and outstanding shares of common stock (the "Warrant Beneficial Ownership Limitation"), and the percentage set forth in this Item 4(b) gives effect to the Warrant Beneficial Ownership Limitation. Consequently, due to the Warrant Beneficial Ownership Limitation, as of the date of the event which requires filing of this statement, the Reporting Person could not exercise all of the Pre-Funded Warrants.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>3,958,332. See Item 4(a).</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>3,958,332. See Item 4(a).</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Exhibit A - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Esousa Group Holdings LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Michael Wachs</signature>
        <title>Michael Wachs/Managing Member</title>
        <date>02/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Michael Wachs</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Michael Wachs</signature>
        <title>Michael Wachs</title>
        <date>02/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)
<SEQUENCE>2
<FILENAME>tm256774d1_ex99-a.htm
<DESCRIPTION>EXHIBIT A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENT REGARDING JOINT FILING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF STATEMENT ON SCHEDULE 13D OR 13G</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned agree to file jointly with the
Securities and Exchange Commission (the &ldquo;SEC&rdquo;) any and all statements on Schedule 13D or Schedule 13G (and any amendments
or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases
and sales by the undersigned of the securities of Nukkleus Inc. until such time as the undersigned file with the SEC a statement terminating
this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 14, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">ESOUSA GROUP HOLDINGS LLC</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Michael Wachs</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Michael Wachs</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;</TD>
    <TD>Managing Member</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">/s/ Michael Wachs</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Michael Wachs</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
